Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

Table 4

UK SSAT029 trial: changes in CNS adverse events by treatment arm, to Week 12.

	Etravirine∗ (𝑛=20)	Efavirenz∗ (𝑛=18)
Grades 2–4 CNS adverse events
All Grades 2–4 CNS adverse events	60%	81%
Median number of CNS adverse events	1	3
Dizziness	15%	19%
Depression	20%	19%
Insomnia	37%	60%
Anxiety	25%	44%
Impaired concentration	30%	31%
Headache	5%	25%
Somnolence	30%	31%
Fatigue	35%	44%
Abnormal dreams	20%	63%
Nervousness	9%	29%
Hallucinations	0%	7%

∗Patients in the delayed (efavirenz) arm switched to etravirine at Week 12; patients in the immediate etravirine arm remained on etravirine after Week 12.